Fri, Aug 1, 2014, 11:00 AM EDT - U.S. Markets close in 5 hrs.


% | $
Click the to save as a favorite.

Ohr Pharmaceutical, Inc. Message Board

  • investrforever investrforever Apr 3, 2014 7:26 AM Flag

    No institutional investors here

    I have read a bit about squalamine and it SOUNDS terrific as it is an eye drop instead of an injection. However, if it had truly great potential - then there would be a lot of institutional investors here. Adam Feurenstein does not believe S is prove to be successful. It failed to work before.

    Be careful here folks - this is a "make it or break it" type investment. Is the risk really worth it?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • really? you buy and sell what #$%$-Adam has to say? and why should anyone listen to you? barely worth a reply.

    • I almost spit my coffee out reading your ridiculous post. Go back and assess what you wrote.

      • 1 Reply to dubl2dz
      • According to YAHOO - less than 1% of the shares are owned by institutional investors.

        This is a HIGH RISK venture. As many on this board have observed, the drs (specialists) don't see an eye drop being effective to treat a back of the eye disease.

        This drug was tried before and failed.

        If phase II is not a big hit - it is LIGHTS OUT.

        I know that so many of you have drunk L10's koolaid --

        I am not invested here. I have, however, been burned by biotechs before - and being sucked in by the so called board "experts" (i.e. L10).

        I do believe that Adam F is a pretty good analyst when it come to biotech investing. He has gotten some wrong for sure, but he has also gotten a lot right.

        I wish you all luck b/c I have been there before - but this does not seem like a good bet to me at all.

8.99-0.01(-0.11%)11:00 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.